These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11525358)

  • 1. Enhanced immunogenicity of recombinant hepatitis B vaccine in exposed family contacts of chronic liver disease patients.
    Thakur V; Guptan RC; Basir SF; Parvez MK; Sarin SK
    Scand J Infect Dis; 2001; 33(8):618-21. PubMed ID: 11525358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults.
    Wang Y; Chen T; Lu LL; Wang M; Wang D; Yao H; Fan C; Qi J; Zhang Y; Qu C
    Vaccine; 2017 Feb; 35(7):1064-1070. PubMed ID: 28069363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hepatitis B infection within family contacts of chronic liver disease patients--does HBeAg positivity really matter?
    Thakur V; Guptan RC; Malhotra V; Basir SF; Sarin SK
    J Assoc Physicians India; 2002 Nov; 50():1386-94. PubMed ID: 12583467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds.
    Tsebe KV; Burnett RJ; Hlungwani NP; Sibara MM; Venter PA; Mphahlele MJ
    Vaccine; 2001 Jul; 19(28-29):3919-26. PubMed ID: 11427266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus infection assessed 3 to 18 years after vaccination in Cuban children and adolescents born to HBsAg-positive mothers.
    Rodríguez Lay LLA; Bello Corredor M; Montalvo Villalba MC; Chibás Ojeda AG; Sariego Frómeta S; Diaz González M; Abad Lamoth Y; Sánchez Wong M; Sausy A; Muller CP; Hübschen JM
    Arch Virol; 2017 Aug; 162(8):2393-2396. PubMed ID: 28439708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India.
    Sukriti ; Pati NT; Sethi A; Agrawal K; Agrawal K; Kumar GT; Kumar M; Kaanan AT; Sarin SK
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1710-5. PubMed ID: 18761556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya- Egypt.
    Salama II; Sami SM; Salama SI; Foud WA; Abdel Hamid AT; Said ZN
    Egypt J Immunol; 2014; 21(1):13-26. PubMed ID: 25204041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan.
    Su FH; Bai CH; Chu FY; Lin YS; Su CT; Yeh CC
    Vaccine; 2012 Jun; 30(27):4034-9. PubMed ID: 22531558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.
    Cheah BC; Davies J; Singh GR; Wood N; Jackson K; Littlejohn M; Davison B; McIntyre P; Locarnini S; Davis JS; Tong SYC
    Vaccine; 2018 Jun; 36(24):3533-3540. PubMed ID: 29735323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low prevalence of hepatitis B vaccine escape mutants among individuals born after the initiation of a nationwide vaccination program in Iran.
    Aghasadeghi MR; Velayati AA; Mamishi S; Nabavi M; Aghakhani A; Bidari-Zerehpoosh F; Haghi Ashtiani MT; Sabeti S; Banifazl M; Azimian-Zavareh F; Motevalli F; Soleymani S; Ramezani A
    Arch Virol; 2016 Dec; 161(12):3405-3411. PubMed ID: 27613286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply.
    Zheng X; Ye X; Du P; Zeng J; Zhu W; Yang B; Li C; Allain JP
    Transfusion; 2015 Apr; 55(4):890-7. PubMed ID: 25363504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of HBV Infection, Vaccine-Induced Immunity, and Susceptibility Among At-Risk Populations: US Households, 2013-2018.
    Roberts H; Ly KN; Yin S; Hughes E; Teshale E; Jiles R
    Hepatology; 2021 Nov; 74(5):2353-2365. PubMed ID: 34097776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs.
    Kabir A; Keshvari M; Kashani AH; Alavian SM
    Hum Vaccin; 2008; 4(5):379-83. PubMed ID: 18398305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of hepatitis B vaccine in susceptible spouses of chronic hepatitis B virus infected individuals at the time of marriage.
    Roushan MR; Samie H; Amiri MJ
    Saudi Med J; 2007 Apr; 28(4):540-3. PubMed ID: 17457474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers.
    Zhou S; Li T; Allain JP; Zhou B; Zhang Y; Zhong M; Fu Y; Li C
    J Med Virol; 2017 Dec; 89(12):2130-2137. PubMed ID: 28543299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada.
    Huynh C; Minuk GY; Uhanova J; Baikie M; Wong T; Osiowy C
    Vaccine; 2017 Aug; 35(35 Pt B):4515-4522. PubMed ID: 28736196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection.
    Yalcin K; Danis R; Degertekin H; Alp MN; Tekes S; Budak T
    J Clin Gastroenterol; 2003 Oct; 37(4):330-5. PubMed ID: 14506391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.